Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 31, 2014 08:00 ET | Source: NephroGenex, Inc.

NephroGenex, Inc. Reports Year-End 2013 Financial Results

Raised over $37 million in gross proceeds during Feb. 2014 Initial Public Offering Obtained SPA for shortened Phase 3 PIONEER clinical program in diabetic nephropathy Entered...
March 27, 2014 08:00 ET | Source: NephroGenex, Inc.

NephroGenex Announces Research Collaborations for Pivotal Studies of Pyridorin(TM) in Diabetic Nephropathy

RESEARCH TRIANGLE PARK, N.C., March 27, 2014 (GLOBE NEWSWIRE) -- NephroGenex, Inc.(Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today...
February 14, 2014 11:30 ET | Source: NephroGenex, Inc.

NephroGenex Announces Closing of Initial Public Offering

RESEARCH TRIANGLE PARK, N.C., Feb. 14, 2014 (GLOBE NEWSWIRE) -- NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today...
February 10, 2014 18:49 ET | Source: NephroGenex, Inc.

NephroGenex Prices Initial Public Offering of Common Stock

RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2014 (GLOBE NEWSWIRE) -- NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today...